GenMark Diagnostics Investigator-Initiated Studies (IIS)
GenMark is committed to continued research efforts through Investigator Initiated Studies, designed and implemented in collaboration with the GenMark Scientific and Medical Affairs Team. Our areas of interest include, but are not limited to, improving patient outcomes, clinical utility, Antimicrobial Stewardship, health economic impact and cost-effectiveness of our ePlex and eSensor XT-8 Systems. The Investigator is responsible for designing and conducting the scientific investigation and complying with institutional requirements where the study will be conducted and all relevant laws, regulations and guidelines for clinical research. GenMark may offer a level of support for the IIS in the form of instrumentation, test panels, funding, and/or technical input and support.
The IIS has been designed so that any investigator is able to submit a form regardless of commercial acquisition of GenMark products belonging to the ePlex and eSensor XT-8 systems. Prioritization will be given to studies that can provide meaningful outcomes based on scientific merit and alignment with the long-term goals and objectives of GenMark. We encourage investigators to ensure that their goals are aligned with area of interests above. While all data is important, we believe the analytical sensitivity of our platforms has been well established and would like to note that priority will be given to studies that have clinically-focused outcomes.
GenMark accepts applications on a rolling basis until all funding for the fiscal year has been exhausted. Then, the acceptance window will close until budgets for the following year have been allocated.
Once the Application Package has been completed, it should be submitted to our Scientific and Medical Affairs Team at ScientificAffairs@genmarkdx.com for review. Review of application packages takes approximately 1 month. Notification of approval will be by e-mail, and if additional study documents are required for final review, they will be requested.